The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...

Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Secondary Progressive Multiple Sclerosis (SPMS).

Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

Tyrosine kinase inhibitors (TKIs) are a class of targeted cancer therapies designed to block the action of tyrosine kinases, enzymes that play a key role in cellular functions such as growth, division ...

DelveInsight's Hematology Market Insights report provides the current and forecast market analysis, individual leading ...

The hematology market is experiencing significant growth driven by the increasing prevalence of blood-related disorders, advancements in research and product development, and the rising number ...

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

Fintel reports that on December 10, 2024, BTIG initiated coverage of Nurix Therapeutics (NasdaqGM:NRIX) with a Buy ...